Fabry's disease medical therapy: Difference between revisions
Jump to navigation
Jump to search
Jose Loyola (talk | contribs) No edit summary |
Jose Loyola (talk | contribs) |
||
| Line 29: | Line 29: | ||
*Indication: Patient with amenable GLA gene variants | *Indication: Patient with amenable GLA gene variants | ||
*Drug: | *Drug: | ||
**Migalastat: 123mg once every other day | **Migalastat: 123mg PO once every other day | ||
===Symptom and Complication Treatments=== | ===Symptom and Complication Treatments=== | ||
Revision as of 18:08, 9 May 2022
|
Fabry's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fabry's disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Fabry's disease medical therapy |
|
Risk calculators and risk factors for Fabry's disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
- The mainstay of therapy for Fabry's disease is enzyme replacement.
Medical Therapy
Specific Treatments
Enzyme replacement therapy (ERT):
- Recombinant human enzymes
- Indications:
- There are no specific guidelines for the timing of the treatment initiation
- One suggestion:
- Symptomatic and asymptomatic males (homozygotes)
- Symptomatic females or atypical males
- Drugs:
- Agalsidase alfa (Replagal): 0.2mg/kg IV every two week
- Agalsidase beta (Fabrazyme): 1mgl/kg IV every two weeks
Increase the enzyme activity:
- Stabilize the mutant form of the alpha-galactosidase enzyme and increase its activity.
- Indication: Patient with amenable GLA gene variants
- Drug:
- Migalastat: 123mg PO once every other day
Symptom and Complication Treatments
Kidney disease [1]
- ACE inhibitors and ARBs: can reduce proteinuria and stable GFR in patients with hypertension and Fabry's disease.
- Dialysis: in ESRD
Cardiovascular disease
- Anti-anginal medications[2]
- Antiarrhythmic medications[3]
- Heart failure Medications[4]
Neurological disease
- Neuropathic pain[5]
- Reduce by ERT
- Gabapentin
- Anti-convulsant drugs
- Reduce the risk of stroke[6]
- Antiplatelet (primary and secondary prevention)
References
- ↑ Wanner C, Breunig F (2007). "Fabry nephropathy and the case for adjunctive renal therapy". J Am Soc Nephrol. 18 (9): 2426–8. doi:10.1681/ASN.2007070783. PMID 17699807.
- ↑ O'Mahony C, Elliott P (2010). "Anderson-Fabry disease and the heart". Prog Cardiovasc Dis. 52 (4): 326–35. doi:10.1016/j.pcad.2009.11.002. PMID 20109602.
- ↑ Weidemann F, Maier SK, Störk S, Brunner T, Liu D, Hu K; et al. (2016). "Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy". Am J Cardiol. 118 (2): 264–74. doi:10.1016/j.amjcard.2016.04.033. PMID 27265676.
- ↑ WRITING COMMITTEE MEMBERS. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE; et al. (2013). "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 128 (16): e240–327. doi:10.1161/CIR.0b013e31829e8776. PMID 23741058.
- ↑ Watson JC, Dyck PJ (2015). "Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management". Mayo Clin Proc. 90 (7): 940–51. doi:10.1016/j.mayocp.2015.05.004. PMID 26141332.
- ↑ Moore DF, Kaneski CR, Askari H, Schiffmann R (2007). "The cerebral vasculopathy of Fabry disease". J Neurol Sci. 257 (1–2): 258–63. doi:10.1016/j.jns.2007.01.053. PMID 17362993.